GPR182

Across TCGA pan-cancer cohorts, GPR182 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated GPR182 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher GPR182 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GPR182 expression acts as an unfavorable survival marker.

BLCA, COAD, and LUAD are the cancer types where GPR182 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.195	0.720	.009	18	view →
COAD	OS	Median	All	0.114	0.677	<.001	10	view →
LUAD	OS	Median	All	0.362	0.685	.042	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

GPR182–BLCA (OS)

Open the BLCA breakdown →